A detailed history of Harbour Capital Advisors, LLC transactions in Crispr Therapeutics Ag stock. As of the latest transaction made, Harbour Capital Advisors, LLC holds 8,925 shares of CRSP stock, worth $427,329. This represents 0.1% of its overall portfolio holdings.

Number of Shares
8,925
Previous 9,280 3.83%
Holding current value
$427,329
Previous $501,000 16.37%
% of portfolio
0.1%
Previous 0.12%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 16, 2024

SELL
$44.62 - $62.75 $15,840 - $22,276
-355 Reduced 3.83%
8,925 $419,000
Q2 2024

Jul 12, 2024

BUY
$51.17 - $68.18 $258,408 - $344,309
5,050 Added 119.39%
9,280 $501,000
Q1 2024

Apr 16, 2024

SELL
$60.67 - $89.12 $6,067 - $8,912
-100 Reduced 2.31%
4,230 $288,000
Q4 2023

Jan 05, 2024

BUY
$38.62 - $72.18 $167,224 - $312,539
4,330 New
4,330 $271,000

Others Institutions Holding CRSP

About CRISPR Therapeutics AG


  • Ticker CRSP
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 78,009,296
  • Market Cap $3.74B
  • Description
  • CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....
More about CRSP
Track This Portfolio

Track Harbour Capital Advisors, LLC Portfolio

Follow Harbour Capital Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Harbour Capital Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Harbour Capital Advisors, LLC with notifications on news.